Back to Trials
NCT07680868Recruiting

Caris Chromoseq Data Collection

Caris Science, Inc.

Start Date

7/1/2026

Completion Date

7/1/2029

Summary

The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study and has signed consent form 2. Subject must be 18 or older 3. Subject be diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN) 4. Physician must order or plan to order Caris Chromoseq for their patient 5. Physicians must order or have ordered conventional cytogenetics, FISH, and NGS testing for AML, MDS, or MPN within the same timeframe of Caris Chromoseq without intervening line of therapy. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Patient for whom Caris Chromoseq is not being ordered 2. Patient is pregnant or lactating 3. Patient is not able or willing to provide consent to data collection for this protocol

Interventions

DIAGNOSTIC_TEST

Caris Chromoseq

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic (MDS) / Myeloproliferative (MPN) DiseasesMyelodysplatic SyndromesMyeloproliferative Neoplasm

Locations

Caris Life Sciences

Phoenix, Arizona 85040

United States